Automated Oncentra QA combined integrity checks with independent HDR dose verification
An automated cervical brachytherapy QA system detected preset planning errors and achieved 98.7% mean gamma agreement with Oncentra.
Tag
brachytherapy
GammaTile produced reproducible SFRT-like dose heterogeneity after brain metastasis resection
Across 18 postoperative brain metastasis cavities, GammaTile generated consistent peak–valley heterogeneity, with the nominal 60 Gy prescription approximating D90.
Rectal retractors reduced rectal dose but increased bladder dose in cervical brachytherapy
Rectal retractor use lowered rectal D2cc and was associated with fewer grade ≥2 vaginal adverse events without reducing target coverage.
Centralized MR-guided brachytherapy maintained 95% local control in cervical cancer
Nationwide referral to one MR-IGABT centre kept median treatment time at 50 days and achieved 95% 3-year local control.
Interstitial brachytherapy achieved 94% local control in complex non-melanoma skin cancer
Definitive interstitial or hybrid brachytherapy controlled 94% of difficult BCC/SCC lesions, although 8% developed grade 3–4 late toxicity.
Brachytherapy-integrated hyperthermia remains technically feasible but clinically unproven
Two randomized trials failed to show benefit from brachytherapy-integrated hyperthermia, while inadequate thermal measurement remains a major barrier to clinical validation.
Coronary intravascular brachytherapy prolonged restenosis-free intervals after recurrent in-stent restenosis
Median restenosis-free interval increased from 96 to 350 days after intravascular brachytherapy for repeatedly recurrent coronary in-stent restenosis.
Whole-breast irradiation after perioperative brachytherapy showed no local relapses in selected patients
Among 26 patients receiving whole-breast irradiation after perioperative brachytherapy, 5-year local-relapse-free survival was 100% with no grade ≥3 toxicity.
Definitive pelvic radiotherapy was associated with longer survival in stage IVB cervical cancer
Median survival was 25 versus 18 months with chemotherapy plus definitive pelvic radiotherapy after propensity matching in stage IVB cervical cancer.
Smaller sequential brachytherapy applicators improved dose uniformity on curved surfaces
Smaller modular superficial brachytherapy applicators and sequential placement substantially improved dose uniformity, especially for beta-emitting sources.
Iodine-125 brachytherapy preserved lung function in high-risk NSCLC patients
CT-guided iodine-125 implantation achieved 60.7% one-year response without grade ≥3 pneumonitis in patients with severe pulmonary dysfunction.
Simulation-free vaginal brachytherapy produced low five-year recurrence in high-intermediate-risk endometrial cancer
Five-year vaginal recurrence was 3.6% without verification imaging, versus 1.6% reported in the separate PORTEC-4a brachytherapy cohort.
DWI/ADC changed residual cervical tumor geometry before brachytherapy despite similar overall volumes
Adding DWI/ADC produced substantially different residual GTV geometry before cervical brachytherapy, with a median Dice overlap of only 0.33.
Task-specific deep learning reduced CT metal artifacts in cervical brachytherapy
Task-specific deep learning halved pelvic artifact burden, improved applicator reconstruction to 0.1 mm, and shortened organ contouring by up to 40%.
Iridium-192 boost improved progression-free survival in unresectable hilar cholangiocarcinoma
An iridium-192 boost increased median progression-free survival from 8.6 to 11.2 months, without a significant overall-survival improvement.